Gout is a metabolic disorder secondary to hyperuricemia in which crystals of monosodium urate cause an acute inflammatory response in joints or a foreign body response in the soft tissues or bones. The most common site is the metacarpophalangeal joint of the great toe and the knee. Soft tissue deposits of urate crystals, tophi, occur. It may present clinically with acute onset of severe pain of a joint or as a chronic joint problem. In bones, radiographs may be normal and later present periarticular erosions. With polarized light, the urate crystals in tophi or synovial fluid appear anisotropic. Prognosis in treated disease is generally good. Uricosuric drugs and allopurinol are used for treatment.


Gout Uric acid Storage disease Podagra Urate Metabolic 

Recommended Reading

  1. Bakshi NA, Al-Zaharani H. Bone marrow oxalosis. Blood. 2012;120(1):8.CrossRefPubMedGoogle Scholar
  2. Desmond P, Hennessy O. Skeletal abnormalities in primary oxalosis. Australas Radiol. 1993;37(1):83–5.CrossRefPubMedGoogle Scholar
  3. Dieppe P, Swan A. Identification of crystals in synovial fluid. Ann Rheum Dis. 1999;58:261–3.CrossRefPubMedCentralPubMedGoogle Scholar
  4. Freemont A. Joint diseases. In: Non-neoplastic diseases of bones and joints (Atlas of non-tumor pathology, Fascicle 9). Silver Spring: ARP Press; 2011.Google Scholar
  5. Girish G, Melville DM, Kaeley GS, et al. Imaging appearances in gout. Arthritis. 2013;2012:673401.Google Scholar
  6. Hamburger M, Baraf H, Adamson TC, et al. Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 suppl 1):3–36.CrossRefPubMedGoogle Scholar
  7. Harrold L. New developments in gout. Curr Opin Rheumatol. 2013;25(3):304–9.CrossRefPubMedGoogle Scholar
  8. Ishida T, Dorfman HD, Bullough PG. Tophaceous pseudogout. Hum Pathol. 1995;26(6):587–93.CrossRefPubMedGoogle Scholar
  9. Lioté F, Ea HK. Recent developments in crystal induced inflammation pathogenesis and management. Curr Rheumatol Replace. 2007;9:243–50.CrossRefGoogle Scholar
  10. Reginato AM, Olsen BR. Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? Curr Opin Rheumatol. 2007;19:134–5.CrossRefPubMedGoogle Scholar
  11. Richman KM, Boutin RD, Vaughan LM. Tophaceous pseudogout of the sternoclavicular joint. Am J Roentgenol. 1999;172(6):1587–9.CrossRefGoogle Scholar
  12. Rosenthal AK. Update in calcium deposition diseases. Curr Opin Rheumatol. 2007;19:158–62.CrossRefPubMedGoogle Scholar
  13. Schlesinger N, Moore DF, Sun JD, Schumacher Jr HR. A survey of current evaluation and treatment of gout. J Rheumatol. 2006;33(10):2050–2.PubMedGoogle Scholar
  14. Yamakawa K, Iwasaki H, Ohjimi Y, et al. Tumoral calcium pyrophosphate dihydrate crystal deposition disease. A clinicopathologic analysis of five cases. Pathol Res Pract. 2001;197(7):499–506.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineHospital for Special SurgeryNew YorkUSA

Personalised recommendations